IL1B and COVID-19: Therapeutic strategies in COVID-19 have also evolved, with widespread use of corticosteroids, IL-6 inhibitors, IL-1 blockers, and antiviral agents, all of which may affect inflammation, thrombosis, and secondary infection risk.